CXCR4靶向PET/CT对消化系统肿瘤分期及拟议肿瘤治疗方案的影响
回顾性分析37例晚期消化系统肿瘤患者,比较指南适宜影像(GAI)与[68Ga]Ga-pentixafor PET/CT对分期及拟议肿瘤治疗方案的影响。CXCR4靶向PET/CT导致14/37例(37.8%)分期改变,其中13例降期;10/14例(71.4%)分期改变会影响后续临床决策。作者认为结果不支持将[68Ga]Ga-pentixafor PET/CT广泛用于这些肿瘤的临床分期。
要点
- CXCR4靶向PET/CT导致14/37例(37.8%)消化系统肿瘤患者分期改变。
- 分期改变者中13/14例(92.9%)为降期,1/14例(7.1%)为升期。
- 10/14例(71.4%)分期改变会影响后续临床决策,如需进一步诊断或未能启动抗肿瘤治疗。
核心结论
- [68Ga]Ga-pentixafor PET/CT遗漏了13例消化系统肿瘤患者的肿瘤病灶,导致10例患者出现不恰当的降期和临床治疗。
- 作者认为结果不支持将[68Ga]Ga-pentixafor PET/CT更广泛地用于这些肿瘤实体的临床分期。
研究设计与样本
- 回顾性研究,从PET/CT数据库中识别37例晚期消化系统肿瘤患者,均因潜在诊疗一体化考虑而安排CXCR4靶向[68Ga]Ga-pentixafor PET/CT,且所有受试者同时有指南适宜影像(GAI)可用。
- 肿瘤类型包括胃肠胰神经内分泌肿瘤21/37例(56.8%)、胰腺导管腺癌6/37例(16.2%)、胆管癌5/37例(13.5%)、肝细胞癌4/37例(10.8%)和结直肠癌1/37例(2.7%)。
- 由委员会认证的消化内科医师比较GAI与[68Ga]Ga-pentixafor PET/CT的分期结果及对拟议肿瘤治疗方案的影响。
主要发现
- 与GAI相比,CXCR4靶向PET/CT导致14/37例(37.8%)患者分期改变。
- 14例分期改变者中,1/14例(7.1%)为升期,13/14例(92.9%)为降期。
- 降期患者中,4/14例(28.6%)的分期改变不会引发肿瘤治疗方案的任何改变。
- 其余10/14例(71.4%)患者中,[68Ga]Ga-pentixafor PET/CT的发现会影响后续临床流程,包括需进一步诊断步骤或未能启动抗肿瘤治疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To elucidate the influence of CXC motif chemokine receptor 4 (CXCR4)-directed imaging on staging and proposed oncologic management in patients with digestive system tumors compared with guideline-appropriate imaging (GAI). METHODS: From our PET/CT database, we retrospectively identified 37 patients with advanced digestive system tumors, which had been scheduled for CXCR4-targeted [ 68 Ga]Ga-pentixafor PET/CT for potential theranostic considerations. In all subjects, concurrent GAI was also available. Patients were afflicted with gastroenteropancreatic neuroendocrine neoplasms (21/37 [56.8%]), pancreatic duct adenocarcinoma (6/37 [16.2%]), cholangiocarcinoma (5/37 [13.5%]), hepatocellular carcinoma (4/37 [10.8%]), and colorectal carcinoma (1/37 [2.7%]). Staging results and impact on proposed oncologic management by a board-certified gastroenterologist were compared between GAI and [ 68 Ga]Ga-pentixafor PET/CT. RESULTS: Relative to GAI, CXCR4-directed PET/CT resulted in staging changes in 14 of 37 patients (37.8%). Upstaging was seen in 1 of 14 patients (7.1%), whereas downstaging was recorded in the remaining 13 of 14 patients (92.9%). Among those, staging changes would not have triggered any changes in oncological management in 4 of 14 (28.6%). For the remaining 10 of 14 patients (71.4%), however, findings on [ 68 Ga]Ga-pentixafor PET/CT would have impacted subsequent clinical algorithm, including the necessity for further diagnostic steps or failure to initiate antitumor therapy. CONCLUSION: [ 68 Ga]Ga-pentixafor PET/CT missed tumor lesions in 13 patients with digestive system tumors, which would have led to inappropriate downstaging and clinical treatment of 10 patients. As such, our results do not support a more widespread use of [ 68 Ga]Ga-pentixafor PET/CT for clinical staging in those tumor entities.
引用
- Weich A, Serfling SE, Schlötelburg W, et al. Impact of CXCR4-Directed PET/CT on Staging and Proposed Oncologic Management in Patients With Digestive System Tumors. Clin Nucl Med. 2023. PMID: 37167408. doi:10.1097/RLU.0000000000004674
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。